DR-444 Characterisation and in-depth analysis of the genome, transcriptome and clinical correlates of metastatic prostate cancer patients for identifying potential druggable targets
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-444 Characterisation and in-depth analysis of the genome, transcriptome and clinical correlates of metastatic prostate cancer patients for identifying potential druggable targets
In this project we aim to use whole genome and whole transcriptome sequencing data to identify druggable targets for novel …
DR-442 Graph-based modeling of host-microbiome interactions to identify functional modules associated with cancer progression
This project aims to uncover how interactions between the human host and microbes within metastatic tumors influence cancer behavior. We …
DR-435 The role of SMC5/6 in colorectal cancer genome stability
Colorectal cancers have high levels of mutations and genome instability. While this enables tumors to become metastatic, it also may …
DR-433 Comparative flux balance analysis of metabolic networks in metastases across multiple cancer types
Tumours often exhibit different metabolic features than non-cancerous tissue. However, studying metabolism in patients has technical limitations that hold back …
DR-430 New transcriptional subgroups of colorectal cancer patients harbouring the BRAF V600E mutation
Colorectal cancer (CRC) remains the second most common cause of cancer death in the world. Approximately 12 % of CRC patients have a mutation in the …
DR-427 The role of whole genome doubling in cancer evolution and diagnostics
Whole genome doubling (WGD) is one of the most frequent aberrations that disrupt the genome of cancers. WGD is associated …
DR-424 Dissecting cancer cell-intrinsic mechanisms dictating the immune landscape of cancer
Immunotherapy has shown great success in treating multiple cancer types. However, not all patients benefit from immunotherapy. We are studying why …
DR-422 Investigating the mechanisms of epithelial/mesenchymal plasticity and metastasis
Metastasis to distant organs is the major cause of cancer-related deaths. The recent advancements in DNA sequencing technology, have significantly …
DR-432 Exploring molecular mechanisms involved in lung cancer progression and prediction of clinical outcomes
This project aims to improve lung cancer treatment by studying the complete genetic makeup of cancer cells. We will use …
DR-404 PRIME-ROSE
The PRIME-ROSE project (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials) is a European initiative to make targeted therapies—originally …
DR-361 A systematic analysis for the cancer fitness landscape between primary and metastatic tumors
We aim to demonstrate that the optimal activity-fitness level (cancer fitness) of cancer genes can vary depending on the tumor …
DR-425 Investigation of mutational processes and selection in cancer metastases
Cancer is a genetic disease driven by mutations in certain parts of the genome. We aim to study the distribution …
Door WGS hebben we in de moleculaire diagnostiek op onze afdeling een stap gemaakt van de analyse van minder dan 100 genen naar circa 20.000 genen per patiënt. Dat levert ontzettend veel waardevolle informatie, niet alleen voor de patiënt van vandaag, maar ook voor de patiënt van de toekomst.